Related Experiment Video
Updated: Aug 18, 2025

10:25
Brain Infarct Segmentation and Registration on MRI or CT for Lesion-symptom Mapping
Published on: September 25, 2019
48.3K
Single-timepoint low-dimensional characterization and classification of acute versus chronic multiple sclerosis
Bastien Caba1, Alexandre Cafaro2, Aurélien Lombard2
1Biogen Digital Health, Biogen, Cambridge, MA, USA.
Neuroimage
|December 6, 2022
Summary
This study introduces a new machine learning method to automatically detect acute multiple sclerosis (MS) lesions using non-contrast MRI scans. The approach enhances early detection of inflammatory disease activity in MS patients.
Area of Science:
- Neuroimaging
- Artificial Intelligence
- Neurology
Background:
- Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease.
- Distinguishing acute from chronic MS lesions is crucial for patient management and clinical trials.
- Current methods using post-gadolinium MRI may underestimate acute lesion activity.
Purpose of the Study:
- To improve the sensitivity of acute MS lesion detection in single-timepoint MRI scans.
- To develop a novel machine learning approach for automatic acute MS lesion detection.
- To utilize conventional non-contrast T1- and T2-weighted brain MRI for enhanced detection.
Main Methods:
- A convolutional neural network was used for image inpainting to generate "lesion-free" reconstructions.
- A multi-objective statistical ranking module evaluated radiomic features from lesion sites.
- An ensemble classifier was optimized using a recursive loop for feature and model selection.
Main Results:
- The method identified a compact textural signature characterizing MS lesion phenotype.
- The approach achieved a balanced accuracy of 74.3-74.6% for acute versus chronic MS lesion classification.
- Validation was performed on fully external cohorts using a patch-level classification task.
Conclusions:
- The developed machine learning method shows promise for sensitive detection of acute MS lesions.
- This approach may improve the assessment of inflammatory disease activity in MS.
- The findings could support clinical decision-making and enhance clinical trial endpoints.

